Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Disoproxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Disoproxil SCHEMBL16237284 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL343783 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3234290 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL2670560 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL29356301 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL18190782 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL40021 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3113154 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL1560984 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL497677 | 0.95 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366712-A1 | GRIFFITHSIN FOR USE IN A METHOD OF PREVENTING OR TREATING INFECTIONS WITH RESPIRATORY VIRUSES | Solmic Biotech GmbH (DE) | 2024-11-07 | — | — | US | disclosed |
| WO-2024104985-A1 | SOMACLONAL VARIATION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2024-05-23 | — | — | WO | disclosed |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9744181-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES INC (US) | 2017-08-17 | — | — | US | disclosed |
| EP-2780348-B1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | LAURUS LABS PRIVATE LTD (IN) | 2017-03-01 | — | — | EP | disclosed |
| US-9457036-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9428815-B2 | HIV-1 reverse transcriptase codon deletion and its use in the management and treatment of HIV infections | EMORY UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160184332-A1 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DRUGS | RATIOPHARM GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-3025718-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2008124192-A2 | NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1583542-B1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES INC (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1923063-A2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070292494-A1 | Carbohydrate-Derivatized Liposomes for Targeting Cellular Carbohydrate Recognition Domains of Ctl/Ctld Lectins, and Intracellular Delivery of Therapeutically Active Compounds | LET THERE BE HOPE MEDICAL RESEARCH INSTITUTE (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007068934-A2 | PHARMACEUTICAL COMBINATION COMPRISING NUCLEOTIDE AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (SUCH AS TENOFOVIR AND LAMIVUDINE) IN DIFFERENT PARTS OF THE DOSAGE UNIT | CIPLA LIMITED (IN) | 2007-06-21 | — | — | WO | disclosed |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20050142114-A1 | Preferentially targeting liposome to mammalian immune cell such as myeloid progenitor cell, monocyte, dendritic cell, macrophage or T-lymphocyte by administering to cell a liposome comprising an active agent and an outer surface that comprises a targeting ligand that binds marker on surface of cell | RODOS BIOTARGET GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040208921-A1 | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-10-21 | — | — | US | disclosed |
| WO-2004064731-A2 | LIPID-DRUG FORMULATIONS AND METHODS FOR TARGETED DELIVERY OF LIPID-DRUG COMPLEXES TO LYMLPLHOID TISSUES | UNIVERSITY OF WASHINGTON (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | DCTD, MTAP, TYMP | FAP 291/4885CYP3A4 471/4885CYP2D6 545/4885 |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | DCTD, TYMP, MTAP | FAP 422/4885CYP3A4 213/4885CYP2D6 233/4885 |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | DCTD, TYMP, MTAP | FAP 422/4885CYP3A4 213/4885CYP2D6 233/4885 |
| US-20160184332-A1 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DRUGS | TYMP, TYMS, ABCB1 | FAP 735/4885CYP3A4 30/4885CYP2D6 92/4885 |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | DCTD, TYMP, MTAP | FAP 422/4885CYP3A4 213/4885CYP2D6 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.